化学查确定了PRMT5作为对抗帕克利塔塞尔三阴性乳腺癌的治疗脆弱性
KeJing Zhang1, Juan Wei2, SheYu Zhang3
1Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310018, China; Department of General Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410083, China; Clinical Research Center for Breast Cancer in Hunan Province, Changsha, Hunan 410000, China.
Cell chemical biology
|September 4, 2024
概括
抗帕克利塔塞尔的三阴性乳腺癌 (TNBC) 显示出对蛋白质氨酸甲基转移酶 (PRMT) 抑制的脆弱性. 向PRMT5可以选择性地诱导耐药细胞中的线粒分裂灾难,从而提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 耐帕克利塔塞尔三阴性乳腺癌 (TNBC) 是一个重大的临床挑战.
- 抵抗的机制涉及到线粒体染色体组合的稳定.
研究的目的:
- 为了确定帕克利塔塞尔耐药性TNBC的新疗法漏洞.
- 研究蛋白质氨酸甲基转移酶 (PRMT) 在介导抗性的作用.
主要方法:
- 在TNBC细胞系中的表观遗传化学探针屏幕.
- 细胞系和临床样本的分析.
- 对PRMT5和I型PRMT的遗传和药理抑制.
- 评估RNA剪接,蛋白质表达和细胞活力.
- 在患者衍生异种移植 (PDX) 模型中进行验证.
主要成果:
- 抗帕克利塔塞尔的TNBC细胞对PRMT抑制具有脆弱性.
- 抑制PRMT5会破坏RNA剪接,特别是光激酶B (AURKB) 的内部保留.
- 这导致AURKB蛋白的表达减少,并导致抗性细胞的选择性线粒分裂灾难.
- 联合抑制I型PRMT和PRMT5,在耐药模型中协同抑制瘤生长.
结论:
- 抑制PRMT代表了对抗帕克利塔塞尔抗性TNBC的有前途的治疗策略.
- 针对PRMT5介导的AURKB调节提供了一种选择性的方法来克服药物耐药性.
- 联合PRMT抑制可能会提高耐药TNBC的治疗疗效.
相关概念视频
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


